POWERFUL NEW CANCER TREATMENTS
Powerful new cancer treatments for brain cancer, head and neck cancer, lung cancer, ocular cancer, gynecologic cancer and prostate cancer from IsoRay Medical, innovators in seed brachytherapy and medical radioisotope applications.
- Cesium-131 is the most significant scientific advancement in cancer brachytherapy in more than 20 years.
- Cesium-131 provides doctors and patients powerful new cancer treatment options using internal radiation or brachytherapy.
- Contact us via the phone number, social media links or by the quick response code below to learn more about seed brachytherapy and medical radioisotope applications, such as brachytherapy prostate seed implant cancer treatment.
WHAT WE DO
IsoRay Medical™ utilizes proprietary technologies to deliver novel brachytherapy approaches to clinicians. IsoRay's Cesium-131 isotope has been used as primary treatment for prostate cancer in over 7,000 patients. As adjuvant radiation therapy, Cesium-131 is being employed in the management of non-small cell lung cancer, intra-cranial tumors (including meningiomas), and head & neck malignancies post-surgical resection.
Additionally, Cesium-131 is currently being used as monotherapy in the management of gynecologic recurrences and ocular melanomas Customized strands, meshes, and applicators are available bearing Cesium-131 sources, and the recently reintroduced GliaSite Radiation Therapy System is available for brachytherapy of the resection bed following surgical removal of gliomas and brain metastases.
RECENTLY IN THE PRESS
- Gynecologic Cancers Successfully Treated Using IsoRay’s Cesium-131 will be Presented by Dr. Jonathan Feddock Saturday Night While at The Society of Gynecologic Oncology Convention (SGO) March 24, 2015
- IsoRay, Inc. Reports Second Quarter Results February 18, 2015
- UPMC Study Reports Isoray’s Cesium-131 Prostate Treatment Provides Strong Cancer Control with Lower Side Effects, Providing Men Improved Quality of Life January 20, 2015
- IsoRay’s Cesium-131 Therapy Takes Center Stage AT Russia’s Neftyanik Hospital a Center of Excellence Providing Cutting Edge Cancer Treatments January 13, 2015
- IsoRay Ranked 5Th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed on the NYSE Group January 12, 2015